Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting [Yahoo! Finance]
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Verrica Pharmaceuticals (VRCA) was downgraded by Zacks Research from "hold" to "strong sell".
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference